Program » Search the meeting program and create your personalized schedule » myISPORBaltimore
(Program subject to change)

Program Tuesday, May 22, 2018

7:00 AM - 6:00 PM
REGISTRATION HELP DESK HOURS (Charles Street Lobby, Baltimore Convention Center)
7:00 AM - 6:00 PM
MULTI-FAITH PRAYER ROOM (Ballroom VIP East Suite (Level 400))
7:00 AM - 6:00 PM
NURSING MOTHER'S ROOM (Ballroom VIP Suite West (Level 400))
8:00 AM - 6:00 PM
SPEAKER READY ROOM HOURS (Room 311 (Level 300))
8:30 AM - 7:45 PM
EXHIBIT/POSTER HALL HOURS (Hall B,C,D, Baltimore Convention Center)
7:15 AM - 8:15 AM
EDUCATIONAL SYMPOSIUM
7:15 AM - 8:15 AM
Room: 309 (Level 300)
SEEING THE FOREST FOR THE TREES: DEVELOPING ROBUST RWE USING DATA LINKAGE

(Sponsored by Covance Market Access)

7:30 AM - 8:30 AM
ISPOR PERSONALIZED/PRECISION MEDICINE SPECIAL INTEREST GROUP
Room: 308 (Level 300)
ISPOR members with a particular interest in health economics and outcomes research as it pertains to cell therapies, gene therapies, and tissue-engineered products are invited to discuss these topics and future projects with leaders of the Personalized/Precision Medicine SIG.
8:30 AM - 2:00 PM
RESEARCH POSTER PRESENTATIONS - SESSION III
8:30 AM - 10:30 AM
WELCOME & SECOND PLENARY SESSION
Room: Hall A (Level 100)
WELCOME FROM ISPOR PRESIDENT
Speaker: Shelby D. Reed, PhD, RPh bio
2017-2018 ISPOR President & Professor, Duke University, Durham, NC, USA
Room: Hall A (Level 100)
WELCOME FROM ISPOR CHIEF SCIENCE OFFICER
Speaker: Richard J. Willke, PhD
Chief Science Officer, ISPOR - The Professional Society for Health Economics and Outcomes Research, Lawrenceville, NJ, USA
Room: Hall A (Level 100)
INCOMING PRESIDENTIAL ADDRESS
Speaker: Federico Augustovski, MD, MSc, PhD
Director, Health Technology Assessment and Health Economics Department, Institute for Clinical Effectiveness and Health Policy (IECS-CONICET), Buenos Aires, Argentina
Room: Hall A (Level 100)
2018 ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARD
AWARDEE: Sherri Rose, PhD
Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Room: Hall A (Level 100)
2018 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
AWARDEE: Laura Hatfield, PhD
Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
Room: Hall A (Level 100)
2018 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH
AWARDEE: Rebecca Myerson, MPH, PhD
Assistant Professor, School of Pharmacy and Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, Los Angeles, CA, USA
Room: Hall A (Level 100)
2018 ISPOR AWARD FOR VALUE IN HEALTH PAPER OF THE YEAR
AWARDEE: Richard Cookson, PhD
Professor, Centre for Health Economics, University of York, York, UK
Room: Hall A (Level 100)
2018 ISPOR MARILYN DIX SMITH LEADERSHIP AWARD
AWARDEE: Finn Børlum Kristensen, PhD, MD
Professor, Health Services Research and Health Technology Assessment, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Room: Hall A (Level 100)
SECOND PLENARY SESSION: DIGITAL HEALTH – HELP OR HYPE?

There is increasing availability and use of digital technologies such as smart phones, social media platforms, and wearables that potentially allow for significant increases in participation in both health-related research and general tracking of health metrics.  This session will provide a balanced overview of where there is reliable evidence that digital technologies have improved health and where there is mainly hype.  The session will address the following questions:

Does the empirical evidence confirm that digital health has actually improved public health?
What evidence is there regarding the global impact of digital health on research?
Has digital health helped to close health disparities’ gaps?
What are ethical concerns surrounding tracking health data and how are they being managed?

Moderator: C. Daniel Mullins, PhD
Professor & Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA
Speaker: Chris A. Jones, DPhil, MSc, FRSM
Network Director Venture Investments, University of Vermont Health Network, Burlington, VT, USA
Speaker: Ejim E. Mark, MD, MPH, MBA
Chief Executive Officer & Founder, Access Healthcare Foundation, Rockville, MD, USA
Speaker: Nadia A. Sam-Agudu, MD
Assistant Professor, Pediatrics, Institute of Human Virology and University of Maryland School of Medicine, and Senior Technical Advisor, Pediatric and Adolescent HIV, Department of Prevention, Care and Treatment and International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria
10:30 AM - 11:00 AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III
11:00 AM - 12:00 PM
BREAKOUT SESSION

11:00 AM - 12:00 PM
Room: Ballroom IV (Level 400)

IP8: HOW IMPORTANT ARE CORE OUTCOME SETS TO MEASURING VALUE OF INNOVATIVE NEW DRUGS?

Moderator:

Elise Berliner, PhD, Director, Technology Assessment Program, Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, Rockville, MD, USA

Panelists:

Chuck Shih, PhD, MHS, Associate Director, Healthcare Reform & Public Policy, Biogen, Washington, DC, USA

Elizabeth Seeley, MS, PhD, Adjunct Lecturer on Health Policy and Management, Department of Health Policy and Management, TH Chan School of Public Health, Harvard University, Boston, MA, USA

Sean R Tunis, MD, MSc, President and Chief Executive Officer, Center for Medical Technology Policy, Baltimore, MD, USA


11:00 AM - 12:00 PM
Room: Ballroom III (Level 400)

IP9: LIES, DAMNED LIES AND COST-EFFECTIVENESS: OPEN-SOURCE MODELS ARE ESSENTIAL IF COST-EFFECTIVENESS ANALYSES ARE TO BE WIDELY ACCEPTED

Moderator:

Neil Hawkins, PhD, Professor of Health Technology Assessment (HTA), Health Economics & Health Technology Assessment, University of Glasgow, Glasgow, UK

Panelists:

Renée J G Arnold, PharmD, Director, Life Sciences, Navigant Consulting, Inc., San Francisco, CA, USA

J. Jaime Caro, MDCM, Adjunct Professor, Medicine, Epidemiology, and Biostatistics, McGill University, Montreal, QC, Canada


11:00 AM - 12:00 PM
Room: Ballroom I (Level 400)
W9: NUMBERS OR NOISE? INTERPRETING INTERNAL VALIDITY TESTS OF STATED-PREFERENCE DATA
Discussion Leaders:

Kathryn O’Callaghan, PhD, Assistant Director of Strategic Programs, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA

F. Reed Johnson, PhD, Professor, Population Health Sciences, School of Medicine, Duke University, Durham, NC, USA

Kevin Marsh, PhD, Executive Director, Outcomes Research, Evidera Ltd, London, UK

Jui-Chen Yang, MEM, Research Economist, Preference Evaluation Research Group, Duke Clinical Research Institute, Durham, NC, USA


11:00 AM - 12:00 PM
Room: Ballroom II (Level 400)
W10: MILLION DOLLAR THERAPIES FOR RARE CONDITIONS: RETHINKING VALUE
Discussion Leaders:

Louis P. Garrison, PhD, Professor Emeritus, The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA

Clifford Goodman, PhD, Senior Vice President and Director, Center for Comparative Effectiveness Research, The Lewin Group, Falls Church, VA, USA

Paul Melmeyer, MPP, Director of Federal Policy, National Organization for Rare Disorders (NORD), Washington, DC, USA


11:00 AM - 12:00 PM
Room: Hall A (Level 100)
W11: CHOOSING THE APPROPRIATE MODELING METHOD: CAUSAL MODELING, HEALTH ECONOMIC MODELING, CONSTRAINED OPTIMIZATION OR SIMULATION?
Discussion Leaders:

William H Crown, PhD, Chief Scientific Officer, OptumLabs, Cambridge, MA, USA

Praveen Thokala, MASc, PhD, Research Fellow, The University of Sheffield, Sheffield, UK

Deborah A Marshall, PhD, Professor, University of Calgary, Calgary, AB, Canada

Kalyan S. Pasupathy, PhD, Faculty, Healthcare Policy & Research and Co- Scientific Director, Healthcare Systems Engineering Program, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA


11:00 AM - 12:00 PM
Room: 309 (Level 300)
P7: CANCER STUDIES
Moderator: Brian Seal, PhD, RPh, MBA
Senior Director HEOR, Astra Zeneca, Gaithersburg, MD, USA

CN1

11:00 AM - 11:15 AM

ECONOMIC GUIDANCE PANEL CHANGES TO MINIMIZE POST-PROGRESSION TREATMENT EFFECTS BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW IN ECONOMIC EVALUATIONS ASSESSING CANCER DRUGS

Samjoo I, Whitney S, Grima A, Grima D
Cornerstone Research Group, Burlington, ON, Canada

CN2

11:15 AM - 11:30 AM

ESTIMATING THE IMPACT OF AFFORDABLE CARE ACT (ACA) ON LIKELIHOOD OF RECEIVING MAMMOGRAPHY AND PAP SMEAR SCREENINGS

Alharbi A, Khan MM
University of South Carolina, Columbia, SC, USA

CN3

11:30 AM - 11:45 AM

HEALTH-RELATED QUALITY OF LIFE ASSESSMENTS PREDICT RELAPSE OR DEATH IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE CONNECT® MM REGISTRY

Wagner I1, Durie BG2, Jagannath S3, Narang M4, Terebelo HR5, Gasparetto C6, Toomey K7, Hardin JW8, Kitali A9, Yue L9, Agarwal A9, Srinivasan S9, Flick ED9, Rifkin RM10, Abonour R11
1Wake Forest University School of Medicine, Winston-Salem, NC, USA, 2Cedars-Sinai Samuel Oschin Cancer Institute, Los Angeles, CA, USA, 3Mount Sinai Hospital, New York, NY, USA, 4Maryland Oncology Hematology, Columbia, MD, USA, 5Providence Hospital and Medical Center, Southfield, MI, USA, 6Duke Cancer Institute, Durham, NC, USA, 7Steeplechase Cancer Center, Somerville, NJ, USA, 8University of South Carolina, Columbia, SC, USA, 9Celgene Corporation, Summit, NJ, USA, 10US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO, USA, 11Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA

CN4

11:45 AM - 12:00 PM

PROJECTING OVERALL SURVIVAL (OS) WITH IMMUNO-ONCOLOGY (IO) TREATMENTS: APPLICATION OF ALTERNATIVE APPROACHES IN METASTATIC MERKEL CELL CARCINOMA (MMCC)

Proskorovsky I1, Lanitis T2, Ambavane A2, Hunger M3, Bharmal M4, Zheng Y5, Phatak H5
1Evidera, Montreal, QC, Canada, 2Evidera, London, UK, 3Mapi, an ICON plc company, Munich, Germany, 4Merck KGaA, Darmstadt, Germany, 5EMD Serono Inc., Rockland, MA, USA

11:00 AM - 12:00 PM
Room: 310 (Level 300)
P8: CARDIOVASCULAR STUDIES
Moderator: Jay Lin, PhD, MBA
Managing Director, Novosys Health, Green Brook, NJ, USA

CV1

11:00 AM - 11:15 AM

NON-INFERIORITY CLINICAL TRIAL DESIGN, DRUG APPROVAL, AND IMPLICATIONS FOR CLINICIANS IN PRESCRIBING ORAL ANTICOAGULANTS

Choi YC1, Vo TN1, Carlson AM2
1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA

CV2

11:15 AM - 11:30 AM

SECONDARY PREVENTION USING CHOLESTEROL-LOWERING MEDICATIONS IN PATIENTS MEETING NEW TREATMENT GUIDELINES: A RETROSPECTIVE COHORT ANALYSIS

Han X1, McCombs JS1, Fox DS1, Chu M1, Dougherty JS2
1University of Southern California, Los Angeles, CA, USA, 2PhRMA, Washington, DC, USA

CV3

11:30 AM - 11:45 AM

COMPARATIVE EFFECTIVENESS OF DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION

Done N1, Li D1, Woolley A2, Rose AJ3, Prentice JC1
1Veterans Health Administration, Boston, MA, USA, 2Bouve College of Health Sciences, Boston, MA, USA, 3RAND Corporation, Boston, MA, USA

CV4

11:45 AM - 12:00 PM

ADHERENCE TO SELF-CARE RECOMMENDATIONS AND ASSOCIATED FACTORS AMONG ADULT HEART FAILURE PATIENTS AT GONDAR UNIVERSITY REFERRAL HOSPITAL, NORTHWEST ETHIOPIA.

Seid MA
University of Gondar, Gondar, Ethiopia
12:00 PM - 2:15 PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
12:30 PM - 12:45 PM
ISPOR GENERAL SPECIAL INTEREST GROUP
Room: 307 (Level 300)
ISPOR members are invited to attend an Open Meeting to learn about the new structure and formation of Special Interest Groups (SIGs) at ISPOR. Information will be available about new SIGs that are in the process of forming. 
12:30 PM - 1:30 PM
EDUCATIONAL SYMPOSIUM
12:30 PM - 1:30 PM
Room: 309 (Level 300)
ADVANCEMENTS IN METHODS OF SURVIVAL BENEFIT ESTIMATION FOR NOVEL ONCOLOGY DRUGS AND THEIR APPLICATIONS IN ICER REVIEWS

(Sponsored by Analysis Group)

12:45 PM - 2:00 PM
ISPOR PATIENT-RESEARCH SPECIAL INTEREST GROUPS
Room: 307 (Level 300)
ISPOR is holding an open meeting to discuss three similar, but different topics related to the patient initiatives at ISPOR. Leadership group members of each of the identified SIGs will discuss the main goal and objectives of their SIG. The group will discuss how each of these topics are related, identify gaps, and generate ideas for each of the groups to focus on. Participants are asked to bring their suggestions and topics that are relevant and would like to see the SIGs develop.  This will include Patient-Reported Outcomes, Patient Centered, Stated Preferences Methods.
12:45 PM - 2:00 PM
ISPOR BIOSIMILAR SPECIAL INTEREST GROUP
Room: 308 (Level 300)
ISPOR members interested in or working with biosimilars are welcome to attend this open meeting. This meeting will discuss the formation of the ISPOR Biosimilar SIG, explore the issues within this space, and identifying projects to address them.
12:45 PM - 2:00 PM
ISPOR MEDICAL DEVICES AND DIAGNOSTICS SPECIAL INTEREST GROUP
Room: 310 (Level 300)
ISPOR members interested in medical devices and diagnostics are encouraged to attend this meeting to identify SIG leadership, suggest topics and projects for the group to develop.
12:45 PM - 2:00 PM
ISPOR NUTRITION ECONOMICS SPECIAL INTEREST GROUP
ISPOR members interested in nutrition economics or medical nutrition are invited to attend.  This meeting will discuss the work of the group to date and identify new topics for the leadership group to address. 
1:00 PM - 2:00 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION III
1:15 PM - 2:00 PM
ISPOR GENERAL BUSINESS MEETING
Room: 316-317 (Level 300)
Attendees are invited to attend ISPOR’s General Business Meeting, the official business meeting of the Society. Members will learn about ISPOR's recent accomplishments and plans for the future and have the opportunity to meet Board members.
2:15 PM - 3:15 PM
BREAKOUT SESSION

2:15 PM - 3:15 PM
Room: Ballroom III (Level 400)

IP10: PRIOR AUTHORIZATION POLICIES FOR MANAGING SPECIALTY DRUG SPENDING IN THE UNITED STATES: CAN WE STRIKE A BALANCE BETWEEN APPROPRIATE UTILIZATION AND APPROPRIATE ACCESS?

Moderator:

Jalpa A. Doshi, PhD, Professor of Medicine, Perelman School of Medicine; Director, Economic Evaluations Unit, Center for Evidence-based Practice; Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA

Panelists:

Steven Miller, MD, MBA, Senior Vice President and Chief Medical Officer, Express Scripts, St. Louis, MO, USA

Cat Davis Ahmed, MBA, Vice President, Policy and Outreach, The FH Foundation, Pasadena, CA, USA

Seth J. Baum, MD, President, Affiliate Professor of Medicine, Schmidt College of Medicine, Florida Atlantic University (FAU), American Society for Preventive Cardiology; Chief Medical Officer, Excel Medical Clinical Trials, Boca Raton, FL, USA


2:15 PM - 3:15 PM
Room: Ballroom I (Level 400)

IP11: “MAKING MEDICINES AFFORDABLE: A NATIONAL IMPERATIVE” – REFLECTIONS ON THE NATIONAL ACADEMIES REPORT (INVITED ISSUE PANEL)

Moderator:

Guru Madhavan, PhD, MBA, Senior Program Officer, Health and Medicine, National Academies of Science, Engineering, and Medicine, Washington, DC, USA

Panelists:

Norman Augustine, MS, Retired, Lockheed Martin Corporation, Bethesda, MD, USA

Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Rochester, NY, USA

Stacie B. Dusetzina, PhD, Associate Professor, Health Policy, Ingram Associate Professor of Cancer Research, Vanderbilt University Medical Center, Nashville, TN, USA

Robert W. Dubois, MD, PhD, Chief Science Officer & Executive Vice President, National Pharmaceutical Council, Washington, DC, USA


2:15 PM - 3:15 PM
Room: Ballroom II (Level 400)
W12: COMPLEX REAL-WORLD EVIDENCE: NETWORKED AND MISSING DATA
Discussion Leaders:

Laura Hatfield, PhD, Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA

Sherri Rose, PhD, Associate Professor, Department of Health Care Policy, Harvard Medical School, Boston, MA, USA

Alisa Stephens-Shields, PhD, Assistant Professor, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA

Amanda Mejia, PhD, Assistant Professor, Department of Statistics, Indiana University, Bloomington, IN, USA

3:15 PM - 3:45 PM
BREAK & EXHIBITS VIEWING
3:30 PM - 7:30 PM
RESEARCH POSTER PRESENTATIONS - SESSION IV
3:45 PM - 4:45 PM
BREAKOUT SESSION

3:45 PM - 4:45 PM
Room: Ballroom I (Level 400)

IP12: WHAT RESEARCH SHOULD BE UNDERTAKEN TO SUPPORT DECISIONS REGARDING THE VALUE OF CURING OR ERADICATING DISEASE?

Moderator:

John Watkins, PharmD, MPH, Pharmacy Manager, Formulary Development, Premera Blue Cross, Mountlake Terrace, WA, USA

Panelists:

Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Steven D. Pearson, MD, MSc, Founder and President, Institute for Clinical and Economic Review, Boston, MA, USA

Carleigh B Krubiner, PhD, Research Scholar and Project Director, Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA


3:45 PM - 4:45 PM
Room: Hall A (Level 100)

IP13: SURROGATE OUTCOMES IN ONCOLOGY: HOW CAN THEY BE USED TO PREDICT OVERALL SURVIVAL IN CLINICAL PRACTICE AND PAYER DECISION MAKING?

Moderator:

Jipan Xie, MD, PhD, Vice President, Analysis Group, Inc., New York, NY, USA

Panelists:

Yiduo Zhang, PhD, Director, Health Economics and Payer Analytics, Global Payer Evidence and Pricing, AstraZeneca, Gaithersburg, MD, USA

Russell Hales, MD, Director, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

Louis P. Garrison, PhD, Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy University of Washington, Seattle, WA, USA


3:45 PM - 4:45 PM
Room: 310 (Level 300)

IP14: DOES MEASURING THE ECONOMIC VALUE OF CLINICAL GENOMIC SEQUENCING REQUIRE NEW METHODOLOGICAL APPROACHES?

Moderator:

Kathryn A. Phillips, PhD, Professor, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California – San Francisco, San Francisco, CA, USA

Panelists:

Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research, Professor, Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Dean A. Regier, PhD, Scientist, Canadian Centre for Applied Research in Cancer Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada

Sarah Wordsworth, PhD, Associate Professor, Nuffield Department of Population Health, University of Oxford, Oxford, UK


3:45 PM - 4:45 PM
Room: Ballroom III (Level 400)
W13: WHAT IS PATIENT-CENTERED AND FIT-FOR-PURPOSE PATIENT PREFERENCE INFORMATION?
Discussion Leaders:

Stephanie Christopher, MA, Program Director, Medical Device Innovation Consortium, Arlington, VA, USA

Anindita Saha, BSE, Director, External Expertise and Partnerships, Center for Devices & Radiological Health (CDRH), US Food & Drug Administration, Silver Spring, MD, USA

A. Brett Hauber, PhD, Senior Economist & Vice President, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA

Margaret Sheehan, JD, Patient Council, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA


3:45 PM - 4:45 PM
Room: Ballroom IV (Level 400)
W14: NETWORK META-ANALYSIS FOR VARIOUS STUDY DESIGNS: STEPPING OUTSIDE THE RANDOMIZED CONTROLLED TRIALS COMFORT ZONE INTO THE REAL WORLD
Discussion Leaders:

Christopher Schmid, PhD, Professor of Biostatistics, School of Public Health, Brown University, Providence, RI, USA

Ashley Pitcher, BSc, DPhil, Engagement Manager, IQVIA, London, UK

Andreas Karabis, PhD, Principal, RWI, IQVIA, Amsterdam, The Netherlands


3:45 PM - 4:45 PM
Room: 309 (Level 300)
P9: HEALTH TECHNOLOGY ASSESSMENT STUDIES
Moderator: Andrew Briggs, DPhil bio
Professor, University of Glasgow, Glasgow, Scotland, UK

HT1

3:45 PM - 4:00 PM

SIMILARITIES AND DIFFERENCES IN EUROPEAN HTA EVIDENCE REQUIREMENTS: ONE FOR ALL OR ONE FOR NONE?

Mordin M1, Fernandez MM2, Pearson I3, Copley-Merriman C1, McBride D3
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3RTI Health Solutions, Manchester, UK

HT2

4:00 PM - 4:15 PM

A HOLISTIC APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF PEMBROLIZUMAB WITH MULTIPLE INDICATIONS: A NORWAY-BASED EXAMPLE

Wu E1, Pellissier J2, Kvamme M3, Irgens K3
1Merck, North Wales, PA, USA, 2Merck & Co., Inc., North Wales, PA, USA, 3MSD Norge A/S, Drammen, Norway

HT3

4:15 PM - 4:30 PM

USING REAL-WORLD EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS: LESSONS AND INSIGHTS FROM REVIEW OF NICE’S TECHNOLOGY ASSESSMENT REPORTS (2016-2017)

Aggarwal S1, Topaloglu O1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

HT4

4:30 PM - 4:45 PM

HEALTH TECHONOLGY ASSESSMENT (HTA) AGENCIES CONSIDERATION OF REAL WORLD EVIDENCE (RWE)

Jao R1, Jaksa A1, Pontynen A1, Wang X2
1Context Matters, New York, NY, USA, 2Celgene Corporation, Summit, NJ, USA

3:45 PM - 4:45 PM
Room: Ballroom II (Level 400)
P10: HEALTHCARE UTILIZATION AND OUTCOMES STUDIES
Moderator: Ebere Onukwugha, MS, PhD 
Associate Professor, University of Maryland School of Pharmacy, Baltimore, MD, USA

HU1

3:45 PM - 4:00 PM

ANNUAL CHANGE IN CONTROLLED SUBSTANCE OPIOID PRESCRIBING AND CONCOMITANT MEDICATIONS FROM AN URBAN ACADEMIC EMERGENCY DEPARTMENT FROM 2011 – 2016

Voelker J1, Crawford A1, Sabonjian M2, Maio V3, Mammen P2
1Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, Philadelphia, PA, USA, 3Thomas Jefferson University, Philadelphia, PA, USA

HU2

4:00 PM - 4:15 PM

COGNITIVE DECLINE WITH ANTICHOLINERGIC MEDICATION USE AMONG ELDERLY NURSING HOME RESIDENTS WITH DEPRESSION

Aparasu RR1, Chatterjee S2, Johnson ML3, Chen H3, Carnahan R4
1Department of Pharmaceutical Health Outcomes and Policy, Houston, TX, USA, 2Novartis Healthcare Pvt Ltd, Hyderabad, India, 3College of Pharmacy, University of Houston, Houston, TX, USA, 4University of Iowa, Iowa City, IA, USA

HU3

4:15 PM - 4:30 PM

INITIATION OF PSYCHOTROPIC PRESCRIPTIONS WITHOUT A PSYCHIATRIC DIAGNOSIS IN US ADULTS

Rhee TG1, Rosenheck RA2
1Yale University School of Medicine, New Haven, CT, USA, 2Yale University School of Medicine, West Haven, CT, USA

HU4

4:30 PM - 4:45 PM

THE USE OF MACHINE LEARNING TO BOOST IDENTIFICATION OF ATRIAL FIBRILLATION AND INCREASE APPROPRIATE UTILIZATION OF ANTICOAGULANT DRUGS

Hertzberg J, Forni A
Optum, Minnetonka, MN, USA
5:00 PM - 6:00 PM
BREAKOUT SESSION

5:00 PM - 6:00 PM
Room: Hall A (Level 100)

IP15: HOW CAN WE ADDRESS THE CURRENT CHALLENGES IN VALUE ASSESSMENT?

Moderator:

Sachin Kamal-Bahl, PhD, VP & Head, Center for Health Systems Innovation & Leadership, Pfizer, Inc., New York, NY, USA

Panelists:

Josh J. Carlson, MPH, PhD, Associate Professor, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA

Shelby D Reed, PhD, RPh, Professor in Medicine, Preference Evaluation Research Group, Duke Clinical Research Institute, Durham, NC, USA

Gillian D Sanders Schmidler, PhD, Deputy Director, Academics and Professor of Population Health Sciences, School of Medicine, The Robert J. Margolis, MD, Center for Health Policy, Duke University, Washington, DC, USA


5:00 PM - 6:00 PM
Room: Ballroom IV (Level 400)

IP16: IN THE ELECTRONIC HEALTH RECORD ERA, DO WE STILL NEED CLINICAL REGISTRIES?

Moderator:

Lisa M. Wruck, PhD, Director, Center for Predictive Medicine, Duke Clinical Research Institute, Durham, NC, USA

Panelists:

Sharon Hensley Alford, PhD, Associate Chief Health Officer, IBM Watson Health, Cambridge, MA, USA

Marc Berger, MD, Consultant, Self Employed, New York, NY, USA

Tracy Wang, MD, MHS, Associate Professor of Medicine, Duke Clinical Research Institute, Duke School of Medicine, Durham, NC, USA


5:00 PM - 6:00 PM
Room: Ballroom II (Level 400)

IP17: HAS THE TIME COME TO REPLACE RANDOMIZED CONTROLLED TRIALS WITH REAL-WORLD DATA -- A CASE OF MEDICAL DEVICES?

Moderator:

Rok Hren, PhD, MSc, Assistant Professor, University of Ljubljana, Ljubljana, Slovenia

Panelists:

Katarzyna Kolasa, PhD, Professor of Health Economics, Head of Department, Health Economics and Healthcare Management, Kozminski University, Warszawa, Poland

Rosanna Tarricone, Associate SDA Dean, Government, Health and Non Profit Division, Centre for Research on Health and Social Care Management (CeRGAS), SDA Bocconi School of Management, Milan, Italy

Cynthia Iglesias, PhD, Senior Research Fellow, Centre for Health Economics, University of York, York, UK


5:00 PM - 6:00 PM
Room: Ballroom III (Level 400)
W15: PATIENT INVOLVEMENT THROUGHOUT THE STAGES OF PATIENT-REPORTED OUTCOME DEVELOPMENT AND CLINICAL TRIAL IMPLEMENTATION
Discussion Leaders:

Sarah L Knight, BSc, MSc, Consultant, Clinical Outcomes Assessment Team, DRG Abacus, Bicester, UK

Helen Kitchen, MSc, Senior Consultant, Clinical Outcomes Assessment, DRG Abacus, Manchester, UK

Ann Hartry, PhD, Vice President, Health Economics and Outcomes Research (HEOR), Lundbeck, Deerfield, IL, USA

Cindy Coney, M.Ed, BSc, President, and Patient Advocate, Monarch Training and Consulting, Tampa, FL, USA


5:00 PM - 6:00 PM
Room: Ballroom I (Level 400)
W16: CHOOSING HOW TO CHOOSE: COLLECTIVE DECISION MAKING IN HEALTHCARE ORGANIZATIONS
Discussion Leaders:

Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Rochester, NY, USA

Guru Madhavan, PhD, MBA, Senior Program Officer, Health and Medicine, National Academies of Science, Engineering, and Medicine, Washington, DC, USA


5:00 PM - 6:00 PM
Room: 309 (Level 300)
P11: MEDICATION ADHERENCE STUDIES
Moderator: Julia Slejko, PhD, BA
Assistant Professor, University of Maryland School of Pharmacy, Baltimore, MD, USA

AD1

5:00 PM - 5:15 PM

THE ASSOCIATION BETWEEN ANTI-EPILEPTIC DRUG ADHERENCE TO SODIUM CHANNEL BLOCKERS AND HEALTH-RELATED QUALITY OF LIFE: ANALYSIS OF US SURVEY DATA FROM PATIENTS WITH EPILEPSY

Lee LK1, Rajagopalan K2
1Kantar Health, San Mateo, CA, USA, 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA

AD2

5:15 PM - 5:30 PM

MODIFIED DRUG ADHERENCE WORK-UP (M-DRAW) TOOL IN PATIENTS WITH DIABETES AT VETERANS AFFAIRS HEALTH SYSTEM: TOOL VALIDATION AND PRELIMINARY RESULT

Lee S1, Gogineni H1, Bae-Shaaw Y2, Worley M3, Law A1
1Western University of Health Sciences, Pomona, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3Ohio State University, Columbus, OH, USA

AD3

5:30 PM - 5:45 PM

ADHERENCE ISSUES IN FIBROMYALGIA: HOW CAN ACCEPTANCE MEASUREMENT HELP UNDERSTANDING PATIENTS' CONCERNS AND WORKING ON SOLUTIONS?

Wiederkehr S1, de Bock E1, Chekroun M2, Arnould B1
1Mapi, An ICON plc Company, Patient-Centered Outcomes, Lyon, France, 2Carenity, Paris, France

AD4

5:45 PM - 6:00 PM

DISCONTINUATION, SWITCHING AND RESTARTING AMONG MIGRAINE PATIENTS INITIATING PROPHYLAXIS

Bonafede MM1, Wilson KL1, Xue F2, Chia VM3, Porter JK4, Desai P2
1Truven Health Analytics, an IBM Company, Cambridge, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen Inc, Thousand Oaks, CA, USA, 4Amgen (Europe) GmbH, Zug, Switzerland

5:00 PM - 6:00 PM
Room: 310 (Level 300)
P12: COST-EFFECTIVENESS ANTIVIRAL STUDIES
Moderator: Sonya J. Snedecor, PhD
Executive Director, Health Economics, Pharmerit International, Bethesda, MD, USA

AV1

5:00 PM - 5:15 PM

COST-EFFECTIVENESS OF STAGED DIRECT-ACTING ANTIVIRAL TREATMENT POLICIES IN AN INTEGRATED HEALTHCARE SYSTEM

Karmarkar T1, Gaskin DJ1, Rodriguez CV2, Padula WV1
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Kaiser Permanente, Rockville, MD, USA

AV2

5:15 PM - 5:30 PM

COST-EFFECTIVENESS ANALYSIS OF BASELINE TESTING FOR RESISTANCE-ASSOCIATED POLYMORPHISMS TO OPTIMISE TREATMENT DURATION IN GENOTYPE 1 NON-CIRRHOTIC TREATMENT-NAÏVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS

Fawsitt CG1, Vickerman P1, Cooke G2, Welton NJ1
1University of Bristol, Bristol, UK, 2Imperial College London, London, UK

AV3

5:30 PM - 5:45 PM

DOLUTEGRAVIR AND RILPIVIRINE TO TREAT VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV-1: A CANADIAN COST-UTILITY ANALYSIS

Arthurs E1, Ward T2, Darlington O2, Sugrue D2, Martin AA3, Cartier SE4, Lee A4, Becker DL4, Punekar YS5, McEwan P2
1GSK, Mississauga, ON, Canada, 2Health Economics & Outcomes Research Ltd, Cardiff, UK, 3GSK, Uxbridge, UK, 4Optum, Burlington, ON, Canada, 5ViiV Healthcare, Brentford, Middlesex, UK

AV4

5:45 PM - 6:00 PM

COST-EFFECTIVENESS ANALYSIS OF UNIVERSAL VS TARGETED HUMAN IMMUNODEFICIENCY VIRUS (HIV) SCREENING APPROACHES TO IDENTIFY NEW HIV DIAGNOSES IN THE EMERGENCY DEPARTMENT (ED)

Batista AE1, Bartolome L1, Nelson F2, Maio V1, Mammen P2
1Thomas Jefferson University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, Philadelphia, PA, USA
6:00 PM - 7:45 PM
EXHIBITORS' WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV
6:15 PM - 7:15 PM
BREAKOUT SESSION

6:15 PM - 7:15 PM
Room: Ballroom IV (Level 400)
F6: VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS EMERGING GOOD PRACTICES TASK FORCE: FINAL RECOMMENDATIONS
Moderator:

Rachael Fleurence, PhD, Executive Director, National Evaluation System for Health Technology Coordinating Center (NESTcc), Medical Device Innovation Consortium (MDIC), Arlington, VA, USA

Speakers:

Lotte Steuten, PhD, MSc, Associate Professor & Director, Health Economics, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Anirban Basu, PhD, Stergachis Family Endowed Professor & Director, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA

Gillian D Sanders Schmidler, PhD, Deputy Director, Academics and Professor of Population Health Sciences, School of Medicine, The Robert J. Margolis, MD, Center for Health Policy, Duke University, Washington, DC, USA

James F. Murray, PhD, Research Fellow, Global Health Outcomes - COE, Eli Lilly and Company, Carmel, IN, USA


6:15 PM - 7:15 PM
Room: Ballroom I (Level 400)
F7: ENABLING ISPOR MEMBER AND PATIENT ADVOCACY GROUP RESEARCH COLLABORATION: A VOLUNTEER PLAN
Moderator:

Richard J. Willke, PhD, Chief Science Officer, ISPOR, Lawrenceville, NJ, USA bio

Speakers:

Laura T. Pizzi, PharmD, MPH, Professor and Director, Center for Health Outcomes Policy and Economics, Rutgers University, Piscataway, NJ, USA

Jason Harris, BA, Associate Director of Policy and Programs, National Health Council, Washington, DC, USA

Brian Ung, PharmD, MS, Post-Doctoral Fellow, US Health Economics and Outcomes Research, Celgene Corporation, Summit, NJ, USA


6:15 PM - 7:15 PM
Room: Ballroom II (Level 400)
F8: REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC?
Moderator:

Jitendar Sharma, PhD, CEO, Andhra Pradesh MedTech Zone Limited, Andhra Pradesh, India

Speakers:

Sukyeong Kim, PhD, Senior Research Fellow, Evidence-based Research Department, National Evidence-Based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)

Makoto Kobayashi, PhD, M.Eng., Director and COO, CRECON Medical Assessment Inc., Tokyo, Japan

Chee-Jen Chang, PhD, Professor and Director, Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City, Taiwan

Jianwei Xuan, MD, PhD, Director, Health Economic Research Institute, School of Pharmacy, Sun Yat-Sen University, Guangzhou, China


6:15 PM - 7:15 PM
Room: Ballroom III (Level 400)
F9: NEW DEVELOPMENTS OF VALUE-BASED PAYMENT ARRANGEMENTS AND VALUE DEMONSTRATION IN LATIN AMERICAN HEALTH SYSTEMS
Moderator:

Juan Carlos Alandete Manotas, MD, MSc, MPH, MACS LATAM, Bayer, Whippany, NJ, USA

Speakers:

Louis Garrison, PhD, Professor Emeritus, CHOICE Institute, University of Washington, Seattle, WA, USA

Ramiro E. Gilardino, MD, MSc, Director, Global Networks Latin America, ISPOR, Lawrenceville, NJ, USA

Boxiong Tang, MD, PhD, Senior Director, Global Health Economics and Outcomes Research (GHEOR), Teva Pharmaceutical, Frazer, PA, USA

6:30 PM - 7:30 PM
POSTER AUTHOR DISCUSSION HOUR - SESSION IV
9:00 PM - 11:00 PM
ISPOR SOCIAL EVENT

Join us for an evening of networking, light bar bites, and live music at the ISPOR Social Event at Tin Roof Baltimore. Known as the “Live Music Joint, where Everybody is Somebody,” Tin Roof offers a fun, inviting, eclectic, laid-back atmosphere. Conveniently located in Baltimore’s popular Power Plant Live and only 1 block away from the world famous Downtown Inner Harbor. So whether you are coming to dance or to grab a drink, this is the perfect opportunity to reconnect with your ISPOR peers! Separate registration required.

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.